Immunogenicity and safety of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine in healthy adults: randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trialsClinical Trial Published on 2021-04-282022-10-05 Journal: Chinese medical journal [Category] SARS, 임상, [키워드] acute respiratory syndrome administration Adults adverse event anti-receptor-binding domain antibody Chinese clinical trial conducted coronavirus Day dose doses double-blind effective Efficacy Endpoint enrolled healthy immune response immunogenicity Immunoglobulin inactivated Inactivated vaccine incidence induce Infection intensity morbidity and mortality neutralization nine participant Phase 1 phase 1 trial phase 2 trial Phase 3 Placebo placebo-controlled placebo-controlled trial primary immunogenicity proportion Randomized receive receiving regimen regimens reported robust Safe SARS-CoV-2 SARS-CoV-2 vaccine second dose serious AE Seroconversion Seven Support treatment groups Trial Vaccine vaccine doses Vaccines [DOI] 10.1097/CM9.0000000000001573 PMC 바로가기 [Article Type] Clinical Trial
Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19COVID-19에 대한 Ad26.COV2.S 백신의 면역원성Clinical Trial Published on 2021-04-202022-09-12 Journal: JAMA [Category] MERS, 임상, 진단, [키워드] Ad26.COV2.S Ad26.COV2.S vaccine Administered age antibody Antibody Response Antiviral binding binding antibody Boston CD4+ CD8+ T-cell cellular immune responses clinical trial conducted Control COVID-19 COVID-19 pandemic determine double-blind Effective vaccines Efficacy end point enrolled evaluate Follow-up function geometric mean titer groups humans humoral immune response immunization immunogenicity initial interim analysis intracellular cytokine staining Intramuscular injection magnitude male Massachusetts median age neutralization neutralizing antibody Neutralizing antibody response outcome participant phase 1 study Phase 3 phenotype Placebo placebo-controlled Randomized receive Receptor binding recipient recipients response Safe SARS-CoV-2 spike-specific T-cell responses Trial Vaccine variety viral particle women [DOI] 10.1001/jama.2021.3645 PMC 바로가기 [Article Type] Clinical Trial
The efficacy of N-Acetylcysteine in severe COVID-19 patients: A structured summary of a study protocol for a randomised controlled trial중증 COVID-19 환자에서 N-아세틸시스테인의 효능: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약Letter Published on 2021-04-122022-09-10 Journal: Trials [Category] 임상, [키워드] 1:1 Acetylcysteine Activation Acute respiratory infection addition Admission All participant All participants antioxidant effect antioxidant effects appearance approved Arm assigned Bandar Abba Bandar Abbas baseline Blinding block randomization Care caused cell damage clinical clinical condition clinical trial clinical trials Committee comparator Comparator group composite endpoint control group Controlled clinical trial COVID-19 discharge dissemination dose Effects Efficacy element ethics committee evaluate excluded expected FIVE Health Health care help Hospitalization hypersensitivity Hypoxemia infiltration inflammatory factors injection intensive care intensive care unit Intervention intervention group Intravenous injection investigator Lactate lactate dehydrogenase LDH lead Local lung lung failure lymphopenia mechanical ventilation Medical Science Medical Sciences medication minute N-acetylcysteine number objective outcome oxygen oxygen partial pressure parallel-group partial pressure participant Patient patients Pharmaceutical Company Phase 3 Placebo positive PCR test Pregnancy primary endpoint principal investigator Progressive protocol random randomised randomised controlled trial randomization Randomized Randomly reactive oxygen species receive recruitment Registered registry reported respiration rate respiratory infection Saline Sample size SARI SARS-CoV-2 virus sequence severe COVID-19 severe COVID-19 patient severe COVID-19 patients Side effect Standard Standard of care Sterile sterile water Study protocol supplementary material technology test results the ethics committee the patient the SARS-CoV-2 virus Treatment Trial registration university water water for injection website were measured written consent [DOI] 10.1186/s13063-021-05242-4 PMC 바로가기 [Article Type] Letter
Genetic variability in COVID-19-related genes in the Brazilian populationArticle Published on 2021-04-022022-10-04 Journal: Human Genome Variation [Category] 유전자 메커니즘, [키워드] 1000 Genomes Project 1KGP ABO ACE2 ACE2 gene Affect allele frequency Analysis analyzed angiotensin-converting enzyme 2 Brazil Brazilian Brazilians candidate gene CCR9 Clinical prognosis contribute country COVID-19 COVID-19 case COVID-19 infection COVID-19 patients COVID-19 severity CTSL CXCR6 database disease DQB1 DRB1 examined Exome exomes explain FYCO1 gene sequence genetic background genetic study genetic variability Genetic variation Genome gnomAD help highest HLA allele Host host cells human lung cells identify IL6 Immunity implicated individual individual level infect Infection infection with SARS-CoV-2 Influenza virus information International investigated life-threatening loci LZTFL1 nonsynonymous Other Patient Phase 3 Pneumonia Population predicted previous study Protein Rare variants rate of infection recent receptor recorded reported risk SARS-CoV-2 SARS-COV-2 infection Seven shown SLC6A20 suggested susceptibility therapeutic targets TMPRSS2 transmembrane serine protease type I interferon unique university Variability variant Variation viral infection XCR1 [DOI] 10.1038/s41439-021-00146-w PMC 바로가기 [Article Type] Article
Letter to the editor on “Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial” by Udwadia et alCorrespondence Published on 2021-04-012022-10-05 Journal: International Journal of Infectious Diseases [Category] SARS, 임상, [키워드] Favipiravir inhibitor Mild-to-moderate multicenter Open-label Phase 3 Randomized RNA-dependent RNA polymerase [DOI] 10.1016/j.ijid.2021.02.035 [Article Type] Correspondence
Response to the comments received on article “Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial” by Udwadia et alCorrespondence Published on 2021-04-012022-10-05 Journal: International Journal of Infectious Diseases [Category] SARS, 임상, [키워드] Favipiravir inhibitor Mild-to-moderate multicenter Open-label Phase 3 Randomized response RNA-dependent RNA polymerase [DOI] 10.1016/j.ijid.2021.02.028 [Article Type] Correspondence
The social experience of participation in a COVID-19 vaccine trial: Subjects’ motivations, others’ concerns, and insights for vaccine promotionResearch article Published on 2021-04-012022-10-05 Journal: Vaccine [Category] SARS, 임상, [키워드] addressed age analyzed appear approval approved attribute city clinical trial COVID-19 COVID-19 vaccination COVID-19 vaccine demographic groups described distribution Effectiveness ENhance expressing Health help identify identity Interaction offer participant Pfizer/BioNTech Phase 3 populations qualitative research receiving reported Research Result Safe Side effect Side effects Support the vaccine transcript Trial vaccination Vaccine Vaccine development Vaccine hesitancy Vaccine uptake while [DOI] 10.1016/j.vaccine.2021.03.036 [Article Type] Research article
RETRACTED ARTICLE: Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial철회된 기사: COVID-19 관리에서 favipiravir 대 hydroxychloroquine의 안전성 및 효능: 무작위 대조 시험Randomized Controlled Trial Published on 2021-03-312022-08-13 Journal: Scientific Reports [Category] 임상, 치료법, 치료제, [키워드] Acute heart failure Acute myocarditis Ain Shams University Hospital Arm Assiut University Hospital average clinical trial Comorbidities comparable COVID-19 demographic characteristics Diagnosis died Drug discovery effective Efficacy enrolled Favipiravir followed by FVP heart failure Heartburn Hydroxychloroquine infected patients management Mild moderate Moderate COVID-19 myocarditis nausea negativity Open-label oral oseltamivir oseltamivir Patient PCR PCR negativity Phase 3 Potential treatment randomised controlled trial randomized-controlled recruited reported Safe Safety SARS-CoV-2 PCR transaminitis Treatment university Viral viral infections [DOI] 10.1038/s41598-021-85227-0 PMC 바로가기 [Article Type] Randomized Controlled Trial
Case study of a critically ill person with COVID-19 on ECMO successfully treated with leronlimabCase report Published on 2021-03-232022-10-30 Journal: Journal of Translational Autoimmunity [Category] COVID-19, [키워드] Administered Analysis approach approval baseline case study CCR5 chemokine Chemokine receptor Clinical improvement confirmed case Coronavirus disease 2019 Coronavirus-disease-2019-(COVID-19) country COVID-19 COVID-19 treatment Critical Critically ill Critically ill patient Day demonstrated Dexamethasone discharged disrupt dose dysregulated ECMO effective elevated evade Evidence extracorporeal membrane oxygenation Extracorporeal-membrane-oxygenation-(ECMO) first dose Hospitalization Host immune response IgG4 immune function immune response improvement infection with SARS-CoV-2 inflammatory cells intensive care Leronlimab Ligand male Mild-to-moderate monoclonal antibody morbidity and mortality Mortality NEWS2 pandemic participant Phase 3 Placebo placebo-controlled Randomized receiving receptor recruitment released reported SARS-CoV-2 SARS-CoV-2 vaccine score severe disease shown Standard of care subject subset survival treated Treatment treatment of HIV treatments for COVID-19 Trial triggered urgency vaccination Vaccines variant virus was reduced with COVID-19 [DOI] 10.1016/j.jtauto.2021.100097 PMC 바로가기 [Article Type] Case report
Immunogenicity of clinically relevant SARS-CoV-2 vaccines in nonhuman primates and humansReview Published on 2021-03-192022-10-04 Journal: Science Advances [Category] SARS, 임상, 진단, [키워드] acute respiratory syndrome antibody candidate clinical trials clinically coronavirus coronavirus disease doses Efficacy evaluated experiment Human humans immunized immunogenicity induce macaques Multiple NHP NHPs outcome pandemic performed Phase 3 protective response protocol Release resulting SARS-CoV-2 vaccine T cell the vaccine Trial trials Vaccine Variation virus [DOI] 10.1126/sciadv.abe8065 PMC 바로가기 [Article Type] Review